Evorpacept + Trastuzumab + Ramucirumab + Paclitaxel (ASPEN-06)
2L/3L Advanced HER2+ Gastric/GEJ Adenocarcinoma
Phase 2/3Active, not recruiting
Key Facts
Indication
2L/3L Advanced HER2+ Gastric/GEJ Adenocarcinoma
Phase
Phase 2/3
Status
Active, not recruiting
Company
About ALX Oncology
ALX Oncology is a clinical-stage biotech focused on developing evorpacept, a next-generation CD47 inhibitor engineered to minimize toxicity while promoting macrophage-mediated tumor destruction. The company's core strategy is to develop evorpacept as a synergistic backbone therapy in combination with established and emerging oncology agents, with multiple Phase 2 trials underway. Key achievements include establishing proof-of-concept in gastric cancer and securing strategic collaborations with major pharmaceutical partners to expand its clinical reach.
View full company profile